Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Jean Brown Research
706
mi
from 98109
Salt Lake City, UT
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Jean Brown Research
706
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  12/31/1969
Figtree Private Hospital
7790
mi
from 98109
Figtree,
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 12/31/1969
Figtree Private Hospital
7790
mi
from 98109
Figtree,
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
1113
mi
from 98109
Scottsdale, AZ
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
1113
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Colorado Blood Cancer Institute
1021
mi
from 98109
Denver, CO
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Colorado Blood Cancer Institute
1021
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Emory University
2178
mi
from 98109
Atlanta, GA
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Emory University
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center Cancer Center
1733
mi
from 98109
Chicago, IL
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center Cancer Center
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Indiana University Simon Cancer Center
1867
mi
from 98109
Indianapolis, IN
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Indiana University Simon Cancer Center
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Kansas University Cancer Center
1495
mi
from 98109
Kansas City, KA
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Kansas University Cancer Center
1495
mi
from 98109
Kansas City, KA
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
1393
mi
from 98109
Minneapolis, MN
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
2110
mi
from 98109
Buffalo, NY
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
2110
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Baylor Sammons Cancer Center
1681
mi
from 98109
Dallas, TX
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Baylor Sammons Cancer Center
1681
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Methodist Healthcare System of San Antonio
1780
mi
from 98109
San Antonio, TX
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Methodist Healthcare System of San Antonio
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
0
mi
from 98109
Seattle, WA
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
0
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian-Weill Cornell Medical Center
2402
mi
from 98109
New York, NY
Selecting a Favorable KIR Donor in Unrelated HCT for AML
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian-Weill Cornell Medical Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Gulf Long-Term Follow-Up Study
Gulf Long-Term Follow-Up Study
Status: Enrolling
Updated:  12/31/1969
NIEHS, Research Triangle Park
2341
mi
from 98109
Research Triangle Park, NC
Gulf Long-Term Follow-Up Study
Gulf Long-Term Follow-Up Study
Status: Enrolling
Updated: 12/31/1969
NIEHS, Research Triangle Park
2341
mi
from 98109
Research Triangle Park, NC
Click here to add this to my saved trials
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Who Progressed or Are Resistant to Hypomethylating Agents
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
2522
mi
from 98109
Tampa, FL
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Who Progressed or Are Resistant to Hypomethylating Agents
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
St. Jude Medical Center
978
mi
from 98109
Fullerton, CA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
St. Jude Medical Center
978
mi
from 98109
Fullerton, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Pacific Shores Medical Group
981
mi
from 98109
Long Beach, CA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Pacific Shores Medical Group
981
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
UCLA
979
mi
from 98109
Los Angeles, CA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
UCLA
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Central Coast Medical Oncology
881
mi
from 98109
Santa Maria, CA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Central Coast Medical Oncology
881
mi
from 98109
Santa Maria, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Collaborative Research Group
2701
mi
from 98109
Boynton Beach, FL
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Collaborative Research Group
2701
mi
from 98109
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
John Theurer Cancer Center at the Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
John Theurer Cancer Center at the Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Weill Cornell -New York Presbyterian Hospital
2262
mi
from 98109
New York, NY
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Weill Cornell -New York Presbyterian Hospital
2262
mi
from 98109
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Chattanooga Hem/Oncology Ass (SCRI)
2083
mi
from 98109
Chattanooga, TN
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Chattanooga Hem/Oncology Ass (SCRI)
2083
mi
from 98109
Chattanooga, TN
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
1971
mi
from 98109
Nashville, TN
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
University of Virginia Medical Center
2284
mi
from 98109
Charlottesville, VA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
University of Virginia Medical Center
2284
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance
0
mi
from 98109
Seattle, WA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance
0
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
1616
mi
from 98109
Madison, WI
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
1616
mi
from 98109
Madison, WI
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Center
705
mi
from 98109
Stanford, CA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Center
705
mi
from 98109
Stanford, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute
2179
mi
from 98109
Atlanta, GA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute
2179
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Northwestern University - Robert H Lurie Comprehensive Cancer Center
1732
mi
from 98109
Chicago, IL
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Northwestern University - Robert H Lurie Comprehensive Cancer Center
1732
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
University of Medicine & Dentistry NJ
2388
mi
from 98109
New Brunswick, NJ
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
University of Medicine & Dentistry NJ
2388
mi
from 98109
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
2403
mi
from 98109
New York, NY
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
2403
mi
from 98109
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Charles A. Sammons Cancer Center
1681
mi
from 98109
Dallas, TX
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Charles A. Sammons Cancer Center
1681
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
CHU Morvan
2222
mi
from 98109
Brest,
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
CHU Morvan
2222
mi
from 98109
Brest,
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated:  12/31/1969
South Carolina Oncology Associates, PA
2317
mi
from 98109
Columbia, SC
Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status: Enrolling
Updated: 12/31/1969
South Carolina Oncology Associates, PA
2317
mi
from 98109
Columbia, SC
Click here to add this to my saved trials
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
2279
mi
from 98109
Winston-Salem, NC
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials